Caffeine

Effects

elevated heartrateincrease in cognitive abilitiesphysical agitationpanicked thinkingracing thoughtsuncomfortable bodyload TS

Overview

Caffeine (also known as 1,3,7-Trimethylxanthine) is a naturally-occurring stimulant substance of the xanthine class. Notable effects include stimulation, wakefulness, enhanced focus and motivation. It is the most widely consumed psychoactive substance in the world. PW

Caffeine is a a CNS stimulant, and also the most widely used psychoactive substance in the world. It is legal and unregulated in most parts of the world, and is found in many commonly sold products. It has a good safety profile, though regular heavy use can cause physical dependence and contribute to certain medical conditions. TS

Caffeine is a central nervous system (CNS) stimulant of the methylxanthine class and is the most commonly consumed psychoactive drug globally. It is mainly used for its eugeroic (wakefulness promoting), ergogenic (physical performance-enhancing), or nootropic (cognitive-enhancing) properties (particularly in workplace settings); it is also used recreationally, often in social settings. Caffeine acts by blocking the binding of adenosine at a number of adenosine receptor types, inhibiting the centrally depressant effects of adenosine and enhancing the release of acetylcholine. Caffeine has a three-dimensional structure similar to that of adenosine, which allows it to bind and block its receptors. Caffeine also increases cyclic AMP levels through nonselective inhibition of phosphodiesterase, increases calcium release from intracellular stores, and antagonizes GABA receptors, although these mechanisms typically occur at concentrations beyond usual human consumption.[1–7] WP

Caffeine is a bitter, white crystalline purine, a methylxanthine alkaloid, and is chemically related to the adenine and guanine bases of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). It is found in the seeds, fruits, nuts, or leaves of a number of plants native to Africa, East Asia, and South America and helps to protect them against herbivores and from competition by preventing the germination of nearby seeds, as well as encouraging consumption by select animals such as honey bees. The most common sources of caffeine for human consumption are the tea leaves of the Camellia sinensis plant and the coffee bean, the seed of the Coffea plant. Steeping the plant product in water—a process called infusion—extracts the caffeine and other components for various purposes. Caffeine-containing drinks, such as tea, coffee, and cola, are consumed globally in high volumes. In 2020, almost 10 million tonnes of coffee beans were consumed globally. Caffeine is the world's most widely consumed psychoactive drug. Unlike most other psychoactive substances, caffeine remains largely unregulated and legal in nearly all parts of the world. Caffeine is seen as socially acceptable in most cultures and is encouraged in some.[8–14] WP⚠ Wikipedia itself has flagged this text: vague.

Caffeine has both positive and negative health effects. It can treat and prevent the premature infant breathing disorders bronchopulmonary dysplasia of prematurity and apnea of prematurity. Caffeine citrate is on the WHO Model List of Essential Medicines. It may confer a modest protective effect against some diseases, including Parkinson's disease. Caffeine can acutely improve reaction time and accuracy for cognitive tasks. Some people experience sleep disruption or anxiety if they consume caffeine, but others show little disturbance. Evidence of a risk during pregnancy is equivocal; some authorities recommend that pregnant women limit caffeine to the equivalent of two cups of coffee per day or less. Caffeine can produce a mild form of drug dependence – associated with withdrawal symptoms such as sleepiness, headache, and irritability – when an individual stops using caffeine after repeated daily intake. Tolerance develops to autonomic effects (blood pressure, heart rate, nervousness) and to alerting/vigilance benefits with regular use. Chronic exposure upregulates adenosine receptors, raising the effort threshold for allocating attention—even to mundane or previously enjoyable tasks—because habitual users operate from a lowered arousal baseline.[15–28] WP

Caffeine is classified by the US Food and Drug Administration (FDA) as generally recognized as safe. Lethal doses, over 10 grams per day for an adult, greatly exceed the typical dose of under 500 milligrams per day. The European Food Safety Authority reported that up to 400 mg of caffeine per day (around 5.7 mg/kg of body mass per day) does not raise safety concerns for non-pregnant adults, while intakes up to 200 mg per day for pregnant and lactating women do not raise safety concerns for the fetus or the breast-fed infants. A 6 ounce cup of coffee typically contains 50–175 mg of caffeine, depending on what "bean" (seed) is used (and how much), how it is roasted, and how it is prepared (e.g., drip, percolation, or espresso). Thus roughly 50–100 ordinary cups of coffee would be required to reach a lethal dose. However, pure powdered caffeine, which is available as a dietary supplement, can be lethal in tablespoon-sized amounts.[29][30][31] WP

History

Chemical identification, isolation, and synthesis

In 1819, the German chemist Friedlieb Ferdinand Runge isolated caffeine for the first time; he called it "Kaffebase" (i.e., a base that exists in coffee). In 1821, caffeine was isolated both by the French chemist Pierre Jean Robiquet and by another pair of French chemists, Pierre-Joseph Pelletier and Joseph Bienaimé Caventou, according to Swedish chemist Jöns Jacob Berzelius in his yearly journal. Furthermore, Berzelius stated that the French chemists had made their discoveries independently of any knowledge of Runge's or each other's work. However, Berzelius later acknowledged Runge's priority in the extraction of caffeine, stating: "However, at this point, it should not remain unmentioned that Runge (in his Phytochemical Discoveries, 1820, pages 146–147) specified the same method and described caffeine under the name Caffeebase a year earlier than Robiquet, to whom the discovery of this substance is usually attributed, having made the first oral announcement about it at a meeting of the Pharmacy Society in Paris."[44][45][46] WP

Pelletier's article on caffeine was the first to use the term in print (in the French form Caféine from the French word for coffee: café). It corroborates Berzelius's account:[47] WP

Caffeine, noun (feminine). Crystallizable substance discovered in coffee in 1821 by Mr. Robiquet. During the same period – while they were searching for quinine in coffee because coffee is considered by several doctors to be a medicine that reduces fevers and because coffee belongs to the same family as the cinchona [quinine] tree – on their part, Messrs. Pelletier and Caventou obtained caffeine; but because their research had a different goal and because their research had not been finished, they left priority on this subject to Mr. Robiquet. We do not know why Mr. Robiquet has not published the analysis of coffee which he read to the Pharmacy Society. Its publication would have allowed us to make caffeine better known and give us accurate ideas of coffee's composition... WP

Robiquet was one of the first to isolate and describe the properties of pure caffeine, whereas Pelletier was the first to perform an elemental analysis.[48][49] WP

In 1827, M. Oudry isolated "théine" from tea, but in 1838 it was proved by Mulder and by Carl Jobst that theine was actually the same as caffeine.[50][51][52] WP

In 1895, German chemist Hermann Emil Fischer (1852–1919) first synthesized caffeine from its chemical components (i.e. a "total synthesis"), and two years later, he also derived the structural formula of the compound. This was part of the work for which Fischer was awarded the Nobel Prize in 1902.[53–58] WP

Legal status

• Caffeine is legal in nearly all parts of the world. However, it is often regulated because it is a psychoactive substance. For example, in the United States, the Food and Drug Administration (FDA) restricts beverages to contain less than 0.02% caffeine. unless they are listed as a dietary supplement.[59][60] PW

Historic regulations

Because it was recognized that coffee contained some compound that acted as a stimulant, first coffee and later also caffeine has sometimes been subject to regulation. For example, in the 16th century Islamists in Mecca and in the Ottoman Empire made coffee illegal for some classes. Charles II of England tried to ban it in 1676, Frederick II of Prussia banned it in 1777, and coffee was banned in Sweden at various times between 1756 and 1823.[61–64] WP

In 1911, caffeine became the focus of one of the earliest documented health scares, when the US government seized 40 barrels and 20 kegs of Coca-Cola syrup in Chattanooga, Tennessee, alleging the caffeine in its drink was "injurious to health". Although the Supreme Court later ruled in favor of Coca-Cola in United States v. Forty Barrels and Twenty Kegs of Coca-Cola, two bills were introduced to the US House of Representatives in 1912 to amend the Pure Food and Drug Act, adding caffeine to the list of "habit-forming" and "deleterious" substances, which must be listed on a product's label.[65][66] WP

United states

The US Food and Drug Administration (FDA) considers safe beverages containing less than 0.02% caffeine; but caffeine powder, which is sold as a dietary supplement, is unregulated. It is a regulatory requirement that the label of most prepackaged foods must declare a list of ingredients, including food additives such as caffeine, in descending order of proportion. However, there is no regulatory provision for mandatory quantitative labeling of caffeine, (e.g., milligrams caffeine per stated serving size). There are a number of food ingredients that naturally contain caffeine. These ingredients must appear in food ingredient lists. However, as is the case for "food additive caffeine", there is no requirement to identify the quantitative amount of caffeine in composite foods containing ingredients that are natural sources of caffeine. While coffee or chocolate are broadly recognized as caffeine sources, some ingredients (e.g., guarana, yerba maté) are likely less recognized as caffeine sources. For these natural sources of caffeine, there is no regulatory provision requiring that a food label identify the presence of caffeine nor state the amount of caffeine present in the food. The FDA guidance was updated in 2018.[59][67][68][69] WP

Consumption

Global consumption of caffeine has been estimated at 120,000 tonnes per year, making it the world's most popular psychoactive substance. The consumption of caffeine has remained stable between 1997 and 2015. Coffee, tea and soft drinks are the most common caffeine sources, with energy drinks contributing little to the total caffeine intake across all age groups.[12][70] WP

Religions

Some religions believe that one is not supposed to consume a non-medical, psychoactive substance, or believe that one is not supposed to consume a substance that is addictive. The Seventh-day Adventist Church asked for its members to "abstain from caffeinated drinks", but has removed this from baptismal vows (while still recommending abstention as policy). The Church of Jesus Christ of Latter-day Saints has said the following with regard to caffeinated beverages: "... the Church revelation spelling out health practices (Doctrine and Covenants 89) does not mention the use of caffeine. The Church's health guidelines prohibit alcoholic drinks, smoking or chewing of tobacco, and 'hot drinks' – taught by Church leaders to refer specifically to tea and coffee."[71][72] WP

Gaudiya Vaishnavas generally also abstain from caffeine, because they believe it clouds the mind and overstimulates the senses. To be initiated under a guru, one must have had no caffeine, alcohol, nicotine or other drugs, for at least a year.[73][74] WP

Caffeinated beverages are widely consumed by Muslims. In the 16th century, some Muslim authorities made unsuccessful attempts to ban them as forbidden "intoxicating beverages" under Islamic dietary laws.[75][76] WP

Pharmacology

Pharmacodynamics

In the absence of caffeine and when a person is awake and alert, little adenosine is present in CNS neurons. With a continued wakeful state, over time adenosine accumulates in the neuronal synapse, in turn binding to and activating adenosine receptors found on certain CNS neurons; when activated, these receptors produce a cellular response that ultimately increases drowsiness. When caffeine is consumed, it antagonizes adenosine receptors; in other words, caffeine prevents adenosine from activating the receptor by blocking the location on the receptor where adenosine binds to it. As a result, caffeine temporarily prevents or relieves drowsiness, and thus maintains or restores alertness.[77] WP

Receptor and ion channel targets

Caffeine is an antagonist of adenosine A2A receptors, and knockout mouse studies have specifically implicated antagonism of the A2A receptor as responsible for the wakefulness-promoting effects of caffeine. Antagonism of A2A receptors in the ventrolateral preoptic area (VLPO) reduces inhibitory GABA neurotransmission to the tuberomammillary nucleus, a histaminergic projection nucleus that activation-dependently promotes arousal. This disinhibition of the tuberomammillary nucleus is the downstream mechanism by which caffeine produces wakefulness-promoting effects. Caffeine is an antagonist of all four adenosine receptor subtypes (A₁, A2A, A2B, and A₃), although with varying potencies. The affinity (KD) values of caffeine for the human adenosine receptors are 12 μM at A₁, 2.4 μM at A2A, 13 μM at A2B, and 80 μM at A₃.[77][78][79] WP

Antagonism of adenosine receptors by caffeine also stimulates the medullary vagal, vasomotor, and respiratory centers, which increases respiratory rate, reduces heart rate, and constricts blood vessels. Adenosine receptor antagonism also promotes neurotransmitter release (e.g., monoamines and acetylcholine), which endows caffeine with its stimulant effects; adenosine acts as an inhibitory neurotransmitter that suppresses activity in the central nervous system. Heart palpitations are caused by blockade of the A₁ receptor.[77][80] WP

Because caffeine is both water- and lipid-soluble, it readily crosses the blood–brain barrier that separates the bloodstream from the interior of the brain. Once in the brain, the principal mode of action is as a nonselective antagonist of adenosine receptors (in other words, an agent that reduces the effects of adenosine). The caffeine molecule is structurally similar to adenosine, and is capable of binding to adenosine receptors on the surface of cells without activating them, thereby acting as a competitive antagonist.[81] WP

In addition to its activity at adenosine receptors, caffeine is an inositol trisphosphate receptor 1 antagonist and a voltage-independent activator of the ryanodine receptors (RYR1, RYR2, and RYR3). It is also a competitive antagonist of the ionotropic glycine receptor.[82][83] WP

Enzyme targets

Caffeine, like other xanthines, also acts as a phosphodiesterase inhibitor. As a competitive nonselective phosphodiesterase inhibitor, caffeine raises intracellular cyclic AMP, activates protein kinase A, inhibits TNF-alpha and leukotriene synthesis, and reduces inflammation and innate immunity. Caffeine also affects the cholinergic system where it is a moderate inhibitor of the enzyme acetylcholinesterase.[5][84–89] WP

Pharmacokinetics

Caffeine from coffee or other beverages is absorbed by the small intestine within 45 minutes of ingestion and distributed throughout all bodily tissues. Peak blood concentration is reached within 1–2 hours. It is eliminated by first-order kinetics. Caffeine can also be absorbed rectally, evidenced by suppositories of ergotamine tartrate and caffeine (for the relief of migraine) and of chlorobutanol and caffeine (for the treatment of hyperemesis). However, rectal absorption is less efficient than oral: the maximum concentration (Cₘₐₓ) and total amount absorbed (AUC) are both about 30% (i.e., 1/3.5) of the oral amounts.[90–95] WP

Caffeine's biological half-life – the time required for the body to eliminate one-half of a dose – varies widely among individuals according to factors such as pregnancy, other drugs, liver enzyme function level (needed for caffeine metabolism) and age. In healthy adults, caffeine's half-life is between 3 and 7 hours. The half-life is decreased by 30–50% in adult male smokers, approximately doubled in women taking oral contraceptives, and prolonged in the last trimester of pregnancy. In newborns the half-life can be 80 hours or more, dropping rapidly with age, possibly to less than the adult value by age 6 months. The antidepressant fluvoxamine (Luvox) reduces the clearance of caffeine by more than 90%, and increases its elimination half-life more than tenfold, from 4.9 hours to 56 hours.[77][96][97] WP

Caffeine is metabolized in the liver by the cytochrome P450 oxidase enzyme system (particularly by the CYP1A2 isozyme) into three dimethylxanthines, each of which has its own effects on the body:[98] WP

• Paraxanthine (84%): Increases lipolysis, leading to elevated glycerol and free fatty acid levels in blood plasma.[98] WP
• Theobromine (12%): Dilates blood vessels and increases urine volume. Theobromine is also the principal alkaloid in the cocoa bean (chocolate).[98] WP
• Theophylline (4%): Relaxes smooth muscles of the bronchi, and is used to treat asthma. The therapeutic dose of theophylline, however, is many times greater than the levels attained from caffeine metabolism.[99] WP

1,3,7-Trimethyluric acid is a minor caffeine metabolite. 7-Methylxanthine is also a metabolite of caffeine. Each of the above metabolites is further metabolized and then excreted in the urine. Caffeine can accumulate in individuals with severe liver disease, increasing its half-life.[77][100][101][102] WP

A 2011 review found that increased caffeine intake was associated with a variation in two genes that increase the rate of caffeine catabolism. Subjects who had this mutation on both chromosomes consumed 40 mg more caffeine per day than others. This is presumably due to the need for a higher intake to achieve a comparable desired effect, not that the gene led to a disposition for greater incentive of habituation.[103] WP

Caffeine can be easily protonated by strong acids to form corresponding caffenium salts. They are of interest because these cations are one of the main species in an acidic medium.[104][105][106] WP

Detection in body fluids

Caffeine can be quantified in blood, plasma, or serum to monitor therapy in neonates, confirm a diagnosis of poisoning, or facilitate a medicolegal death investigation. Plasma caffeine levels are usually in the range of 2–10 mg/L in coffee drinkers, 12–36 mg/L in neonates receiving treatment for apnea, and 40–400 mg/L in victims of acute overdosage. Urinary caffeine concentration is frequently measured in competitive sports programs, for which a level in excess of 15 mg/L is usually considered to represent abuse.[107] WP

Chemistry

Formula

C8H10N4O2 PC

CAS number

58-08-2 PC

Molar mass (g/mol)

194.19 PC

IUPAC name (computed by PubChem)

1,3,7-trimethylpurine-2,6-dione PC

SMILES

CN1C=NC2=C1C(=O)N(C(=O)N2C)C PC

InChIKey

RYYVLZVUVIJVGH-UHFFFAOYSA-N PC

PubChem CID

2519

Pop culture

No references added yet.

References

1. Journal / agency Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Research. Brain Research Reviews. 1992. doi:10.1016/0165-0173(92)90012-B · PMID 1356551
2. Journal / agency Reddy VS, Shiva S, Manikantan S, Ramakrishna S. Pharmacology of caffeine and its effects on the human body. European Journal of Medicinal Chemistry Reports. 2 March 2024. doi:10.1016/j.ejmcr.2024.100138
3. Journal / agency Camfield DA, Stough C, Farrimond J, Scholey AB. Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis. Nutrition Reviews. August 2014. doi:10.1111/nure.12120 · PMID 24946991
4. Journal / agency Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacological Reviews. January 2014. doi:10.1124/pr.112.007054 · PMID 24344115 · PMC3880463
5. Journal / agency Ribeiro JA, Sebastião AM. Caffeine and adenosine. Journal of Alzheimer's Disease. 2010. doi:10.3233/JAD-2010-1379 · PMID 20164566
6. Other Hillis DM, Sadava D, Hill RW, Price MV. Principles of Life. 2015
7. Journal / agency Faudone G, Arifi S, Merk D. The Medicinal Chemistry of Caffeine. Journal of Medicinal Chemistry. June 2021. doi:10.1021/acs.jmedchem.1c00261 · PMID 34019396
8. Other Caballero B, Finglas P, Toldra F. Encyclopedia of Food and Health. 2015
9. Other Myers RL. The 100 Most Important Chemical Compounds: A Reference Guide. 2007
10. Journal / agency Wright GA, Baker DD, Palmer MJ, Stabler D, Mustard JA, Power EF, Borland AM, Stevenson PC. Caffeine in floral nectar enhances a pollinator's memory of reward. Science. March 2013. doi:10.1126/science.1228806 · PMID 23471406 · PMC4521368
11. Other Global coffee consumption, 2020/21
12. Other Burchfield G. What's your poison: caffeine. 1997
13. Journal / agency Ferré S. Caffeine and Substance Use Disorders. Journal of Caffeine Research. June 2013. doi:10.1089/jcr.2013.0015 · PMID 24761274 · PMC3680974
14. Journal / agency Reyes CM, Cornelis MC. Caffeine in the Diet: Country-Level Consumption and Guidelines. Nutrients. November 2018. doi:10.3390/nu10111772 · PMID 30445721 · PMC6266969
15. Journal / agency WHO Model List of Essential Medicines. October 2013
16. Journal / agency Cano-Marquina A, Tarín JJ, Cano A. The impact of coffee on health. Maturitas. May 2013. doi:10.1016/j.maturitas.2013.02.002 · PMID 23465359
17. Journal / agency Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. Geriatrics & Gerontology International. April 2014. doi:10.1111/ggi.12123 · PMID 23879665
18. Journal / agency Kløve K, Petersen A. A systematic review and meta-analysis of the acute effect of caffeine on attention. Psychopharmacology. 7 May 2025. doi:10.1007/s00213-025-06775-1 · PMID 40335666
19. Journal / agency O'Callaghan F, Muurlink O, Reid N. Effects of caffeine on sleep quality and daytime functioning. Risk Management and Healthcare Policy. 7 December 2018. doi:10.2147/RMHP.S156404 · PMID 30573997 · PMC6292246
20. Journal / agency Zhang C, Hu Z, Tang J, Xue J, Lu W. Caffeine intake and anxiety: a meta-analysis. Frontiers in Psychology. 2024. doi:10.3389/fpsyg.2024.1270246 · PMID 38362247 · PMC10867825
21. Journal / agency Gardiner C, Weakley J, Burke L, Roach G, Sargent C, Maniar N, Townshend A, Halson S. The effect of caffeine on subsequent sleep: A systematic review and meta-analysis. Sleep Medicine Reviews. Jun 2023. doi:10.1016/j.smrv.2023.101764 · PMID 36870101
22. Journal / agency Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes. The Cochrane Database of Systematic Reviews. June 2015. doi:10.1002/14651858.CD006965.pub4 · PMID 26058966 · PMC10682844
23. Journal / agency American College of Obstetricians and Gynecologists. ACOG CommitteeOpinion No. 462: Moderate caffeine consumption during pregnancy. Obstetrics and Gynecology. August 2010. doi:10.1097/AOG.0b013e3181eeb2a1 · PMID 20664420
24. Other Malenka RC, Nestler EJ, Hyman SE. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. 2009
25. Other American Psychiatric Association. Substance-Related and Addictive Disorders. 2013
26. Journal / agency Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology. October 2004. doi:10.1007/s00213-004-2000-x · PMID 15448977
27. Journal / agency Robertson D, Wade D, Workman R, Woosley RL, Oates JA. Tolerance to the humoral and hemodynamic effects of caffeine in man. The Journal of Clinical Investigation. April 1981. doi:10.1172/JCI110124 · PMID 7009653 · PMC370671
28. Journal / agency Lee YZ, Chua KN, Voon FL, Tham CL, Ho YC, Lee MT. Neurobiology of chronic caffeine use and withdrawal: Mechanisms, effects and implications. Food and Chemical Toxicology. January 2026. doi:10.1016/j.fct.2025.115817
29. Journal / agency Heckman MA, Weil J, Gonzalez de Mejia E. Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. Journal of Food Science. April 2010. doi:10.1111/j.1750-3841.2010.01561.x · PMID 20492310
30. Journal / agency EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the safety of caffeine. EFSA Journal. 2015. doi:10.2903/j.efsa.2015.4102
31. Journal / agency Awwad S, Issa R, Alnsour L, Albals D, Al-Momani I. Quantification of Caffeine and Chlorogenic Acid in Green and Roasted Coffee Samples Using HPLC-DAD and Evaluation of the Effect of Degree of Roasting on Their Levels. Molecules. December 2021. doi:10.3390/molecules26247502 · PMID 34946584 · PMC8705492
32. Journal / agency Chad J Reissig, Lawrence P Carter, Matthew W Johnson, Miriam Z Mintzer, Margaret A Klinedinst, Roland R Griffiths. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
33. Journal / agency Arthur Eumann Mesas, Luz M Leon-Muñoz, Fernando Rodriguez-Artalejo, Esther Lopez-Garcia. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis
34. Journal / agency M-L Nurminen, L Niittynen, R Korpela & H Vapaatalo. Coffee, caffeine and blood pressure: a critical review
35. Journal / agency Holmgren, P., Nordén-Pettersson, L., Ahlner, J. Caffeine fatalities—four case reports. Forensic Science International. January 2004. doi:10.1016/j.forsciint.2003.09.019
36. Journal / agency Alstott, R. L., Miller, A. J., Forney, R. B. Report of a human fatality due to caffeine. Journal of Forensic Sciences. April 1973
37. Journal / agency Peters, J. M. Factors Affecting Caffeine Toxicity: A Review of the Literature. The Journal of Clinical Pharmacology and The Journal of New Drugs. 6 May 1967. doi:10.1002/j.1552-4604.1967.tb00034.x
38. Journal / agency Klevebrant, Lisa; Frick, Andreas. Effects of caffeine on anxiety and panic attacks in patients with panic disorder: A systematic review and meta-analysis. General Hospital Psychiatry. 2022-01-01. doi:10.1016/j.genhosppsych.2021.11.005 · PMID 34871964
39. Journal / agency Silverman, K., Evans, S. M., Strain, E. C., Griffiths, R. R. Withdrawal Syndrome after the Double-Blind Cessation of Caffeine Consumption. New England Journal of Medicine. 15 October 1992. doi:10.1056/NEJM199210153271601
40. Journal / agency Hedges, D. W., Woon, F. L., Hoopes, S. P. Caffeine-induced psychosis. CNS spectrums. March 2009. doi:10.1017/s1092852900020101
41. Journal / agency Cerimele, J. M., Stern, A. P., Jutras-Aswad, D. Psychosis Following Excessive Ingestion of Energy Drinks in a Patient With Schizophrenia. American Journal of Psychiatry. March 2010. doi:10.1176/appi.ajp.2009.09101456
42. Journal / agency Kuribara, H. Caffeine enhances the stimulant effect of methamphetamine, but may not affect induction of methamphetamine sensitization of ambulation in mice. Psychopharmacology. October 1994. doi:10.1007/BF02245053
43. Journal / agency Fujii, W., Kuribara, H., Tadokoro, S. Interaction between caffeine and methamphetamine by means of ambulatory activity in mice. Yakubutsu, Seishin, Kodo = Japanese Journal of Psychopharmacology. June 1989
44. Other Runge FF. Neueste phytochemische Entdeckungen zur Begründung einer wissenschaftlichen Phytochemie. 1820
45. Other Weinberg BA, Bealer BK. The World of Caffeine: The Science and Culture of the World's Most Popular Drug. 2001
46. Other Berzelius JJ. Jahres-Bericht über die Fortschritte der physischen Wissenschaften von Jacob Berzelius. 1825
47. Other Pelletier PJ. Cafeine. 1822
48. Other Robiquet PJ. Café. 1823
49. Journal / agency Dumas P. Recherches sur la composition élémentaire et sur quelques propriétés caractéristiques des bases salifiables organiques. Annales de Chimie et de Physique. 1823
50. Journal / agency Oudry M. Note sur la Théine. Nouvelle Bibliothèque Médicale. 1827
51. Journal / agency Mulder GJ. Ueber Theïn und Caffeïn. Journal für Praktische Chemie. 1838. doi:10.1002/prac.18380150124
52. Journal / agency Jobst C. Thein identisch mit Caffein. Liebig's Annalen der Chemie und Pharmacie. 1838. doi:10.1002/jlac.18380250106
53. Journal / agency Fischer E. Ueber das Caffeïn. Berichte der Deutschen Chemischen Gesellschaft zu Berlin. 1881. doi:10.1002/cber.188101401142
54. Journal / agency Fischer E. Ueber das Caffeïn. Zweite Mitteilung. Berichte der Deutschen Chemischen Gesellschaft zu Berlin. 1881. doi:10.1002/cber.18810140283
55. Journal / agency Fischer E. Ueber das Caffeïn. Dritte Mitteilung. Berichte der Deutschen Chemischen Gesellschaft zu Berlin. 1882. doi:10.1002/cber.18820150108
56. Journal / agency Fischer E, Ach L. Synthese des Caffeïns. Berichte der Deutschen Chemischen Gesellschaft zu Berlin. 1895. doi:10.1002/cber.189502803156
57. Journal / agency Fischer E. Ueber die Constitution des Caffeïns, Xanthins, Hypoxanthins und verwandter Basen. Berichte der Deutschen Chemischen Gesellschaft zu Berlin. 1897. doi:10.1002/cber.189703001110
58. Other Théel H. Nobel Prize Presentation Speech. 1902
59. Journal / agency CFR - Code of Federal Regulations Title 21
60. Other Consumer Q&A: Caffeine-Containing Dietary Supplements
61. Other Brown DW. A new introduction to Islam. 2004
62. Other Ágoston G, Masters B. Encyclopedia of the Ottoman Empire. 2009
63. Other Hopkins K. Food Stories: The Sultan's Coffee Prohibition. 24 March 2006
64. Other By the King. A PROCLAMATION FOR THE Suppression of Coffee-Houses
65. Journal / agency Benjamin LT, Rogers AM, Rosenbaum A. Coca-Cola, caffeine, and mental deficiency: Harry Hollingworth and the Chattanooga trial of 1911. Journal of the History of the Behavioral Sciences. January 1991. doi:10.1002/1520-6696(199101)27:1<42::AID-JHBS2300270105>3.0.CO;2-1 · PMID 2010614
66. Other The Rise and Fall of Cocaine Cola
67. Other Sanner A. Sudden death of Ohio teen highlights dangers of caffeine powder. 19 July 2014
68. Journal / agency Reissig CJ, Strain EC, Griffiths RR. Caffeinated energy drinks – a growing problem. Drug and Alcohol Dependence. January 2009. doi:10.1016/j.drugalcdep.2008.08.001 · PMID 18809264 · PMC2735818
69. Journal / agency Guidance on Highly Concentrated Caffeine in Dietary Supplements. 16 April 2018
70. Journal / agency Verster JC, Koenig J. Caffeine intake and its sources: A review of national representative studies. Critical Reviews in Food Science and Nutrition. May 2018. doi:10.1080/10408398.2016.1247252 · PMID 28605236
71. Other Robinette GW. The War on Coffee. 2018
72. Other Mormonism in the News: Getting It Right August 29. 2012
73. Other If Krishna does not accept my Chocolates, Who should I offer them to?
74. Other Buxton J. The Politics of Narcotic Drugs: A Survey. 17 December 2010
75. Other Campo JE. Encyclopedia of Islam. 1 January 2009
76. Other Brown DW. A New Introduction to Islam. 24 August 2011
77. Harm reduction site Caffeine. 16 September 2013
78. Journal / agency Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. Journal of Alzheimer's Disease. 14 November 2012. doi:10.3233/JAD-2012-121186 · PMID 22886028
79. Journal / agency Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. J. Neurochem. 2008. doi:10.1111/j.1471-4159.2007.05196.x · PMID 18088379
80. Other World of Caffeine. 15 June 2013
81. Journal / agency Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cellular and Molecular Life Sciences. April 2004. doi:10.1007/s00018-003-3269-3 · PMID 15095008 · PMC11138593
82. Other Caffeine
83. Journal / agency Duan L, Yang J, Slaughter MM. Caffeine inhibition of ionotropic glycine receptors. The Journal of Physiology. August 2009. doi:10.1113/jphysiol.2009.174797 · PMID 19564396 · PMC2756438
84. Journal / agency Essayan DM. Cyclic nucleotide phosphodiesterases. The Journal of Allergy and Clinical Immunology. November 2001. doi:10.1067/mai.2001.119555 · PMID 11692087
85. Journal / agency Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics. June 2008. doi:10.1590/S1807-59322008000300006 · PMID 18568240 · PMC2664230
86. Journal / agency Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. American Journal of Respiratory and Critical Care Medicine. February 1999. doi:10.1164/ajrccm.159.2.9804085 · PMID 9927365
87. Journal / agency Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. Journal of Immunology. January 2005. doi:10.4049/jimmunol.174.2.589 · PMID 15634873
88. Journal / agency Karadsheh N, Kussie P, Linthicum DS. Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives. Toxicology Letters. March 1991. doi:10.1016/0378-4274(91)90015-X · PMID 2003276
89. Journal / agency Pohanka M, Dobes P. Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase. International Journal of Molecular Sciences. May 2013. doi:10.3390/ijms14059873 · PMID 23698772 · PMC3676818
90. Journal / agency Liguori A, Hughes JR, Grass JA. Absorption and subjective effects of caffeine from coffee, cola and capsules. Pharmacology, Biochemistry, and Behavior. November 1997. doi:10.1016/S0091-3057(97)00003-8 · PMID 9329065
91. Journal / agency Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. European Journal of Clinical Pharmacology. 1983. doi:10.1007/bf00613933 · PMID 6832208
92. Journal / agency Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. Plasma and salivary pharmacokinetics of caffeine in man. European Journal of Clinical Pharmacology. 1981. doi:10.1007/BF00609587 · PMID 7333346
93. Journal / agency Graham JR. Rectal use of ergotamine tartrate and caffeine alkaloid for the relief of migraine. The New England Journal of Medicine. June 1954. doi:10.1056/NEJM195406032502203 · PMID 13165929
94. Journal / agency Brødbaek HB, Damkier P. The treatment of hyperemesis gravidarum with chlorobutanol-caffeine rectal suppositories in Denmark: practice and evidence. Ugeskrift for Laeger. May 2007. PMID 17553397
95. Journal / agency Teekachunhatean S, Tosri N, Rojanasthien N, Srichairatanakool S, Sangdee C. Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects. ISRN Pharmacology. 8 January 2013. doi:10.1155/2013/147238 · PMID 23533801 · PMC3603218
96. Journal / agency Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological Reviews. March 1999. doi:10.1016/S0031-6997(24)01396-6 · PMID 10049999
97. Other Drug Interaction: Caffeine Oral and Fluvoxamine Oral
98. Other Caffeine
99. Journal / agency Welsh EJ, Bara A, Barley E, Cates CJ. Caffeine for asthma. The Cochrane Database of Systematic Reviews. January 2010. doi:10.1002/14651858.CD001112.pub2 · PMID 20091514 · PMC7053252
100. Other 7-Methylxanthine
101. Journal / agency Singh H, Singh H, Latief U, Tung GK, Shahtaghi NR, Sahajpal NS, Kaur I, Jain SK. Myopia, its prevalence, current therapeutic strategy and recent developments: A Review. Indian J Ophthalmol. August 2022. doi:10.4103/ijo.IJO_2415_21 · PMID 35918918 · PMC9672758
102. Journal / agency Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. European Journal of Clinical Pharmacology. December 2008. doi:10.1007/s00228-008-0553-z · PMID 18762933
103. Journal / agency Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, Berndt SI, Boerwinkle E, Chanock S, Chatterjee N, Couper D, Curhan G, Heiss G, Hu FB, Hunter DJ, Jacobs K, Jensen MK, Kraft P, Landi MT, Nettleton JA, Purdue MP, Rajaraman P, Rimm EB, Rose LM, Rothman N, Silverman D, Stolzenberg-Solomon R, Subar A, Yeager M, Chasman DI, van Dam RM, Caporaso NE. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLOS Genetics. April 2011. doi:10.1371/journal.pgen.1002033 · PMID 21490707 · PMC3071630
104. Journal / agency Gomberg M. Perhalides of Caffeine. Journal of the American Chemical Society. 1896-04-01. doi:10.1021/ja02090a004
105. Journal / agency Herbstein FH, Kaftory M, Kapon M, Saenger W. Structures of three crystals containing approximately — linear chains of triiodide ions. Zeitschrift für Kristallographie - Crystalline Materials. 1981-01-01. doi:10.1524/zkri.1981.154.1-2.11
106. Journal / agency Merkelbach J, Majewski MA, Reiss GJ. Crystal structure of caffeinium triiodide – caffeine (1/1), C₁₆H₂₁I₃N₈O₄. Zeitschrift für Kristallographie - New Crystal Structures. 2018-09-01. doi:10.1515/ncrs-2018-0125
107. Other Baselt R. Disposition of Toxic Drugs and Chemicals in Man. 2017
108. Journal / agency PubChem. Caffeine

Text and values on this page are quoted from PsychonautWiki (CC BY-SA 4.0), Wikipedia (CC BY-SA 4.0), TripSit factsheets, PubChem (public domain). Each value links to the exact revision it came from.